CTOs on the Move

Omega Therapeutics

www.omegatherapeutics.com

 
Omega Therapeutics is a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programming™ platform. The OMEGA™ platform harnesses the power of epigenetics, the mechanism that controls gene expression and every aspect of an organism`s life from cell genesis, growth and differentiation to cell death. The OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by returning aberrant gene expression to a normal range without altering native nucleic acid sequences. Omega`s engineered, modular, and programmable mRNA-encoded epigenetic medicines, Omega Epigenomic Controllers™, target ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Magenta Therapeutics

Magenta Therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune and blood based diseases.

Artizan Biosciences

Artizan Biosciences, Inc. is a biotechnology company with a mission to restore lives disrupted by inflammatory disease through innovation and advancement of microbiota-targeted therapies. We are leveraging our proprietary IgA-SEQ™ technology platform to distinguish disease-driving bacteria from the intestinal microbiota with the goal of developing new and potentially curative treatments.

XOMA

XOMA is a late-stage biotechnology company with a diverse portfolio of innovative therapeutic antibodies. The Company has built an expertise in allosteric modulation and has applied that expertise to expand the therapeutic potential of monoclonal antibodies.  The first compound from XOMA’s allosteric modulating antibody program is gevokizumab, an IL-1 beta modulating antibody.  XOMA has partnered with SERVIER, a global pharmaceutical company based in France, to develop and commercialize gevokizumab for the global market, and the companies are conducting a global Phase 3 program in people with Behçet’s disease uveitis and non-infectious uveitis. Each company also has a proof-of-concept (POC) clinical program in place to identify other IL-1 mediated diseases that could be treated with gevokizumab.  One of these POC studies led XOMA to select its next Phase 3 indication, pyoderma gangrenosum, a rare ulcerative skin disease. XOMA`s scientific research also produced the XMet program, which consists of three classes of preclinical allosteric modulating antibodies, including Selective Insulin Receptor Modulators (SIRMs) that could have a major impact on the treatment of diabetes.  XOMA will retain the compound that has potential to treat several rare insulin dysfunction-related diseases and to out-license the compounds that could address the diabetes markets. 

Biothera, the Immune Health Company

Biothera, the Immune Health Company is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Precept Life Sciences

Precept Life Sciences is a Reston, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.